TABLE 1.
In vitro growth inhibition of B. divergens, B. canis, and P. falciparum parasites as well as human Jurkat lymphoblasts against antihematozoan drugsa
| Drug | IC50 (nM) against:
|
|||
|---|---|---|---|---|
| B. divergens | B. canis | P. falciparum | Jurkat lymphoblasts | |
| T16 | 28.3 ± 2 (3) | 7 | 1.9 ± 0.3 (5) | 34,330 ± 3,330 (3) |
| Chloroquine | 8,000 | ND | 51.0 ± 0.7 (3) | 21,600 ± 1,600 (5) |
| Pentamidine | 100 | ND | 17 | ND |
| Imidocarb | 100 | ND | 30 | ND |
Cells were incubated with drugs for 8 h (B. divergens and B. canis), 48 h (P. falciparum), or 24 h (human Jurkat lymphoblasts) before adding [3H]hypoxanthine for parasite-infected cells or [3H]thymidine for Jurkat lymphoblasts to determining cell viability. Values are means of at least three independent experiments (indicated in parentheses) conducted at least in duplicate, using different stock drug solutions and different batches of infected erythrocytes (standard errors of the means are indicated). Otherwise, values are means of two independent experiments conducted in triplicate, differing by less than 40%. ND, not done.